Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Melatonin (meta)
Aspirin (meta) Metformin (meta)
Bamlaniv../e.. (meta) Molnupiravir (meta)
Bebtelovimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Cannabidiol (meta) Nitric Oxide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Lactoferrin (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 22% Improvement Relative Risk Mortality (b) 58% Ventilation 9% Ventilation (b) 50% Progression 30% primary Progression (b) 60% primary c19aspirin.com Ghati et al. CTRI/2020/07/026791 RESIST Aspirin RCT LATE Favors aspirin Favors control
Ghati, 661 patient aspirin late treatment RCT: 22% lower mortality [p=0.62], 9% lower ventilation [p=0.8], and 30% lower progression [p=0.46] https://c19p.org/ghati
copied to clipboard
Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial)
Ghati et al., BMC Infectious Diseases, doi:10.1186/s12879-022-07570-5, CTRI/2020/07/026791
9 Jul 2022    Source   PDF   Share   Tweet
RCT hospitalized patients in India, 224 treated with atorvastatin, 225 with aspirin, and 225 with both, showing lower serum interleukin-6 levels with aspirin, but no statistically significant changes in other outcomes. Low dose aspirin 75mg daily for 10 days.
risk of death, 22.1% lower, RR 0.78, p = 0.62, treatment 11 of 442 (2.5%), control 7 of 219 (3.2%), NNT 141, aspirin and aspirin/atorvastatin vs. control, modified intention-to-treat.
risk of death, 57.5% lower, RR 0.42, p = 0.22, treatment 3 of 221 (1.4%), control 7 of 219 (3.2%), NNT 54, aspirin vs. control, modified intention-to-treat.
risk of mechanical ventilation, 9.2% lower, RR 0.91, p = 0.80, treatment 11 of 442 (2.5%), control 6 of 219 (2.7%), NNT 398, aspirin and aspirin/atorvastatin vs. control, modified intention-to-treat.
risk of mechanical ventilation, 50.5% lower, RR 0.50, p = 0.34, treatment 3 of 221 (1.4%), control 6 of 219 (2.7%), NNT 72, aspirin vs. control, modified intention-to-treat.
risk of progression, 30.0% lower, HR 0.70, p = 0.46, treatment 11 of 442 (2.5%), control 7 of 219 (3.2%), NNT 141, aspirin and aspirin/atorvastatin vs. control, Cox proportional hazards, modified intention-to-treat, primary outcome.
risk of progression, 60.0% lower, HR 0.40, p = 0.18, treatment 3 of 221 (1.4%), control 7 of 219 (3.2%), NNT 54, aspirin vs. control, Cox proportional hazards, modified intention-to-treat, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ghati et al., 7/9/2022, Randomized Controlled Trial, India, peer-reviewed, 14 authors, study period 28 July, 2020 - 27 January, 2021, average treatment delay 6.0 days, trial CTRI/2020/07/026791 (RESIST).
Contact: deeptikailath@gmail.com (corresponding author).
All Studies   Meta Analysis
This PaperAspirinAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit